Little Benefit to Breakthrough Cancer Drugs

Abstract

Cancer drugs approved as FDA breakthrough therapies are not necessarily better than those approved through the traditional pathway: Although breakthrough-designated cancer drugs were approved in less time, a recent study reported, they were not associated with gains in progression-free survival or response rates, nor were they safer or more novel than non-breakthrough-designated drugs.